Gyre Therapeutics, Inc. (GYRE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$7.07
Price Target
$17.00
Target Range
$16.00 — $18.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E314.2x
Forward PEG—
Implied Growth—
Median Target$17.00
Analyst Spread11.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$16
+126.3%
Consensus
$17
+140.5%
Bull Case
$18
+154.6%
GYRE Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Gyre Therapeutics, Inc. (GYRE) has a Wall Street consensus price target of $17.00, based on estimates from 1 covering analysts. With the stock currently trading at $7.07, this represents a potential upside of +140.5%. The company has a market capitalization of $686M.
Analyst price targets range from a low of $16.00 to a high of $18.00, representing a 12% spread in expectations. The median target of $17.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GYRE trades at a trailing P/E of 314.2x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+53.3%
Avg Forward P/E28.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HALOHalozyme Therapeutics, Inc. | $7.7B | $65.19 | $78.33 | +20.2% | Buy | 8.1x | 27 |
 ARDXArdelyx, Inc. | $1.7B | $6.98 | $17.00 | +143.6% | Buy | — | 16 |
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 IDYAIDEAYA Biosciences, Inc. | $2.5B | $28.24 | $58.67 | +107.8% | Buy | — | 25 |
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $6.9B | $43.02 | $39.00 | -9.4% | Buy | 32.3x | 13 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
Upside Potential Comparison
ARDXIDYAIMVTINVAPRAXACADRCUSHALOSee GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GYRE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGYRE — Frequently Asked Questions
Quick answers to the most common questions about buying GYRE stock.
What is the GYRE stock price target for 2026?
The consensus Wall Street price target for GYRE is $17, representing 140.5% upside from the current price of $7.07. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GYRE a buy, sell, or hold?
GYRE has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $17 implies 140.5% upside from current levels.
Is GYRE stock overvalued or undervalued?
GYRE's current price is $7.07 with a consensus target of $17 (140.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can GYRE stock go?
The most bullish Wall Street analyst has a price target of $18 for GYRE, while the most conservative target is $16. The consensus of $17 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover GYRE stock?
GYRE is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GYRE stock forecast?
The 12-month GYRE stock forecast based on 1 Wall Street analysts shows a consensus price target of $17, with estimates ranging from $16 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Should I buy GYRE stock?
Wall Street analysts are very optimistic on GYRE, with a "Buy" consensus rating and $17 price target (140.5% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GYRE price targets vary so much?
GYRE analyst price targets range from $16 to $18, a 12% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17 consensus represents the middle ground.